INmune Bio (INMB) 10-Q 5 Nov 20 2020 Q3 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	9 Months Ended
	Sep. 30, 2020	Nov. 05, 2020
Document Information Line Items
Entity Registrant Name	Inmune Bio, Inc.
Document Type	10-Q
Current Fiscal Year End Date	--12-31
Entity Common Stock, Shares Outstanding		13,447,948
Amendment Flag	false
Entity Central Index Key	0001711754
Entity Current Reporting Status	Yes
Entity Filer Category	Non-accelerated Filer
Document Period End Date	Sep. 30, 2020
Document Fiscal Year Focus	2020
Document Fiscal Period Focus	Q3
Entity Small Business	true
Entity Emerging Growth Company	true
Entity Shell Company	false
Entity Ex Transition Period	false
Entity File Number	001-38793
Entity Incorporation, State or Country Code	NV
Entity Interactive Data Current	Yes

Consolidated Balance Sheets (Un

Consolidated Balance Sheets (Unaudited) - USD ($)	Sep. 30, 2020	Dec. 31, 2019
CURRENT ASSETS
Cash and cash equivalents	$ 24,311,153	$ 6,995,525
Research and development tax incentive receivable	1,465,377	568,139
Other tax receivable	143,657	77,225
Prepaid expenses	216,871	97,623
Prepaid expenses – related party		26,266
TOTAL CURRENT ASSETS	26,137,058	7,764,778
Operating lease – right of use asset – related party	165,388	191,543
Acquired in-process research and development intangible assets	16,514,000	16,514,000
TOTAL ASSETS	42,816,446	24,470,321
CURRENT LIABILITIES
Accounts payable and accrued liabilities	1,191,086	401,989
Accounts payable and accrued liabilities – related parties	9,132	290,102
Deferred liabilities	253,709
Operating lease, current liability – related party	20,183	8,288
TOTAL CURRENT LIABILITIES	1,474,110	700,379
Long-term operating lease liability – related party	136,043	160,164
TOTAL LIABILITIES	1,610,153	860,543
COMMITMENTS AND CONTINGENCIES
STOCKHOLDERS’ EQUITY
Preferred stock, $0.001 par value, 10,000,000 shares authorized, 0 shares issued and outstanding
Common stock, $0.001 par value, 200,000,000 shares authorized, 13,447,948 and 10,770,948 shares issued and outstanding, respectively	13,448	10,771
Additional paid-in capital	71,351,634	44,833,703
Common stock issuable	50,000	50,000
Accumulated other comprehensive loss	(37,735)	(8,515)
Accumulated deficit	(30,171,054)	(21,276,181)
TOTAL STOCKHOLDERS’ EQUITY	41,206,293	23,609,778
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	$ 42,816,446	$ 24,470,321

Consolidated Balance Sheets (_2

Consolidated Balance Sheets (Unaudited) (Parentheticals) - $ / shares	Sep. 30, 2020	Dec. 31, 2019
Statement of Financial Position [Abstract]
Preferred stock par value (in Dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized	10,000,000	10,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock par value (in Dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized	200,000,000	200,000,000
Common stock, shares issued	13,447,948	10,770,948
Common stock, shares outstanding	13,447,948	10,770,948

Consolidated Statements of Oper

Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Income Statement [Abstract]
REVENUE
OPERATING EXPENSES
General and administrative	2,456,266	1,916,200	4,960,106	4,550,306
Research and development	2,362,880	1,167,986	4,058,710	2,415,390
Waiver of common stock issuable				(1,542,000)
Total operating expenses	4,819,146	3,084,186	9,018,816	5,423,696
LOSS FROM OPERATIONS	(4,819,146)	(3,084,186)	(9,018,816)	(5,423,696)
OTHER INCOME	102,484	17,220	123,943	63,602
NET LOSS	$ (4,716,662)	$ (3,066,966)	$ (8,894,873)	$ (5,360,094)
Net loss per common share – basic and diluted (in Dollars per share)	$ (0.36)	$ (0.28)	$ (0.77)	$ (0.53)
Weighted average common shares outstanding - basic and diluted (in Shares)	12,926,539	10,762,473	11,496,753	10,105,675
COMPREHENSIVE LOSS
NET LOSS	$ (4,716,662)	$ (3,066,966)	$ (8,894,873)	$ (5,360,094)
Other comprehensive loss on foreign currency translation	(47,861)	(35,542)	(29,220)	(61,278)
Total comprehensive loss	$ (4,764,523)	$ (3,102,508)	$ (8,924,093)	$ (5,421,372)

Consolidated Statement of Chang

Consolidated Statement of Changes in Stockholders’ Equity (Unaudited) - USD ($)	Common Stock	Additional Paid-In Capital	Common Stock Issuable	Accumulated Other Comprehensive Income (loss)	Accumulated Deficit	Total
Balance at Dec. 31, 2018	$ 8,719	$ 25,446,196	$ 4,676,000	$ 6,529	$ (13,597,868)	$ 16,539,576
Balance (in Shares) at Dec. 31, 2018	8,719,441
Issuance of common stock and warrants for cash, net	$ 1,021	7,250,121				7,251,142
Issuance of common stock and warrants for cash, net (in Shares)	1,020,820
Stock-based compensation		974,699				974,699
Stock-based compensation (in Shares)
Gain/Loss on foreign currency translation				(722)		(722)
Net loss					(1,901,045)	(1,901,045)
Balance at Mar. 31, 2019	$ 9,740	33,671,016	4,676,000	5,807	(15,498,913)	22,863,650
Balance (in Shares) at Mar. 31, 2019	9,740,261
Balance at Dec. 31, 2018	$ 8,719	25,446,196	4,676,000	6,529	(13,597,868)	16,539,576
Balance (in Shares) at Dec. 31, 2018	8,719,441
Waiver of common stock issuable						1,542,000
Net loss						(5,360,094)
Balance at Sep. 30, 2019	$ 10,762	43,661,265	50,000	(54,749)	(18,957,962)	24,709,316
Balance (in Shares) at Sep. 30, 2019	10,762,473
Balance at Mar. 31, 2019	$ 9,740	33,671,016	4,676,000	5,807	(15,498,913)	22,863,650
Balance (in Shares) at Mar. 31, 2019	9,740,261
Issuance of common stock for cash, net	$ 622	4,957,257				4,957,879
Issuance of common stock for cash, net (in Shares)	622,212
Issuance of common stock issuable	$ 400	3,083,600	(3,084,000)
Issuance of common stock issuable (in Shares)	400,000
Waiver of common stock issuable			(1,542,000)			(1,542,000)
Waiver of common stock issuable (in Shares)
Stock-based compensation		974,696				974,696
Stock-based compensation (in Shares)
Gain/Loss on foreign currency translation				(25,014)		(25,014)
Net loss					(392,083)	(392,083)
Balance at Jun. 30, 2019	$ 10,762	42,686,569	50,000	(19,207)	(15,890,996)	26,837,128
Balance (in Shares) at Jun. 30, 2019	10,762,473
Waiver of common stock issuable
Stock-based compensation		974,696				974,696
Stock-based compensation (in Shares)
Gain/Loss on foreign currency translation				(35,542)		(35,542)
Net loss					(3,066,966)	(3,066,966)
Balance at Sep. 30, 2019	$ 10,762	43,661,265	50,000	(54,749)	(18,957,962)	24,709,316
Balance (in Shares) at Sep. 30, 2019	10,762,473
Balance at Dec. 31, 2019	$ 10,771	44,833,703	50,000	(8,515)	(21,276,181)	23,609,778
Balance (in Shares) at Dec. 31, 2019	10,770,948
Issuance of common stock for cash, net	$ 196	1,002,448				1,002,644
Issuance of common stock for cash, net (in Shares)	196,000
Acquisition and retirement of common stock	$ (220)	(1,011,780)				(1,012,000)
Acquisition and retirement of common stock (in Shares)	(220,000)
Capital contribution		215,761				215,761
Stock-based compensation		681,705				681,705
Stock-based compensation (in Shares)
Gain/Loss on foreign currency translation				(20,737)		(20,737)
Net loss					(2,070,407)	(2,070,407)
Balance at Mar. 31, 2020	$ 10,747	45,721,837	50,000	(29,252)	(23,346,588)	22,406,744
Balance (in Shares) at Mar. 31, 2020	10,746,948
Balance at Dec. 31, 2019	$ 10,771	44,833,703	50,000	(8,515)	(21,276,181)	23,609,778
Balance (in Shares) at Dec. 31, 2019	10,770,948
Waiver of common stock issuable
Cashless exercise of warrants (in Shares)
Net loss						$ (8,894,873)
Balance at Sep. 30, 2020	$ 13,448	71,351,634	50,000	(37,735)	(30,171,054)	41,206,293
Balance (in Shares) at Sep. 30, 2020	13,447,948
Balance at Mar. 31, 2020	$ 10,747	45,721,837	50,000	(29,252)	(23,346,588)	22,406,744
Balance (in Shares) at Mar. 31, 2020	10,746,948
Issuance of common stock for cash, net	$ 151	664,694				664,845
Issuance of common stock for cash, net (in Shares)	150,682
Stock-based compensation		681,705				681,705
Gain/Loss on foreign currency translation				39,378		39,378
Net loss					(2,107,804)	(2,107,804)
Balance at Jun. 30, 2020	$ 10,898	47,068,236	50,000	10,126	(25,454,392)	21,684,868
Balance (in Shares) at Jun. 30, 2020	10,897,630
Issuance of common stock for cash, net	$ 2,528	23,237,764				23,240,292
Issuance of common stock for cash, net (in Shares)	2,527,918
Waiver of common stock issuable
Cashless exercise of warrants	$ 2	(2)
Cashless exercise of warrants (in Shares)	2,400
Stock-based compensation	$ 20	1,045,636				1,045,656
Stock-based compensation (in Shares)	20,000
Gain/Loss on foreign currency translation				(47,861)		(47,861)
Net loss					(4,716,662)	(4,716,662)
Balance at Sep. 30, 2020	$ 13,448	$ 71,351,634	$ 50,000	$ (37,735)	$ (30,171,054)	$ 41,206,293
Balance (in Shares) at Sep. 30, 2020	13,447,948

Consolidated Statements of Cash

Consolidated Statements of Cash Flows (Unaudited) - USD ($)	9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ (8,894,873)	$ (5,360,094)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation	2,409,066	2,924,091
Waiver of common stock issuable		(1,542,000)
Changes in operating assets and liabilities:
Research and development tax incentive receivable	(897,238)	(361,769)
Other tax receivable	(66,432)	(68,460)
Joint development cost receivable		17,989
Prepaid expenses	(119,248)	(106,478)
Prepaid expenses – related party	26,266	(118,602)
Accounts payable and accrued liabilities	789,097	(215,983)
Accounts payable and accrued liabilities – related parties	(65,209)	(108,434)
Deferred liabilities	253,709
Operating lease liability – related party	13,929	(11,546)
Net cash used in operating activities	(6,550,933)	(4,951,286)
CASH FLOWS FROM FINANCING ACTIVITIES:
Net proceeds from sale of common stock	24,907,781	12,209,021
Purchase of common stock	(1,012,000)
Net cash provided by financing activities	23,895,781	12,209,021
Impact on cash from foreign currency translation	(29,220)	(61,278)
NET INCREASE IN CASH	17,315,628	7,196,457
CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD	6,995,525	186,204
CASH AND CASH EQUIVALENTS AT END OF PERIOD	24,311,153	7,382,661
SUPPLEMENTAL DISCLOSURE OF CASH FLOWS INFORMATION:
Cash paid for income taxes
Cash paid for interest expense
NONCASH INVESTING AND FINANCING ACTIVITIES:
Capital contribution	215,761
Cashless exercise of warrants	2
Issuance of warrants to placement agents		247,452
Issuance of common stock issuable		$ 3,084,000

Organization and Description of

Organization and Description of Business	9 Months Ended
	Sep. 30, 2020
Accounting Policies [Abstract]
ORGANIZATION AND DESCRIPTION OF BUSINESS	NOTE 1 INmune Bio, Inc. (the “Company” or “INmune Bio”) was organized in the State of Nevada on September 25, 2015, and is a clinical stage biotechnology pharmaceutical company focused on developing and commercializing its product candidates to treat diseases where the innate immune system is not functioning normally and contributing to the patient’s disease. INmune Bio has two product platforms. The DN-TNF product platform utilizes dominant-negative technology to selectively neutralize soluble TNF, a key driver of innate immune dysfunction and mechanistic target of many diseases. DN-TNF is currently being developed for COVID-19 complications (Quellor), cancer (INB03), Alzheimer’s and treatment resistant depression (XPro595), and NASH (LIVNate). The Natural Killer Cell Priming Platform includes INKmune aimed at priming the patient’s NK cells to eliminate minimal residual disease in patients with cancer. INmune Bio’s product platforms utilize a precision medicine approach for the treatment of a wide variety of hematologic malignancies, solid tumors and chronic inflammation.

Liquidity

Liquidity	9 Months Ended
	Sep. 30, 2020
Liquidity Disclosure [Abstract]
LIQUIDITY	NOTE 2 As of September 30, 2020, the Company had an accumulated deficit of $30,171,054 and experienced losses since its inception. Losses have principally occurred as a result of non-cash stock-based compensation expense and the substantial resources required for research and development of the Company’s products, which included the general and administrative expenses associated with its organization and product development as well as the lack of sources of revenues until such time as the Company’s products are commercialized. To meet its current and future obligations the Company has taken the following steps to capitalize the business and achieve its business plan: ● During July 2020, the Company completed an underwritten public offering in which it sold 2,500,000 shares of common stock at a public offering price of $10.00 per share. The 2,500,000 shares sold included the full exercise of the underwriters’ option to purchase 326,086 shares at a price of $10.00 per share. Aggregate net proceeds from the underwritten public offering were approximately $23.1 million, net of approximately $1.9 million in underwriting discounts and commissions and offering expenses. ● During April 2020, the Company entered into a sales agreement with BTIG, LLC (“BTIG”), as sales agent, to establish an At-The-Market (“ATM”) offering program. The Company was required to pay BTIG a commission of 3% of the gross proceeds from the sale of shares. The ATM program will remain in full force and effect until the earlier of the sale of all of the shares under the ATM program or the termination of the sales agreement by the Company or BTIG. From April 2020 through September 2020, the Company sold 178,600 shares of common stock at an average price of $5.45 per share for net proceeds of approximately $0.8 million. ● During May 2019, the Company entered into a securities purchase agreement (“Purchase Agreement”) with Lincoln Park Capital Fund LLC (“Lincoln Park”), pursuant to which Lincoln Park has agreed to purchase from the Company up to an aggregate of $20.0 million of common stock of the Company (subject to certain limitations) from time to time over the term of the Purchase Agreement. The extent we rely on Lincoln Park as a source of funding will depend on a number of factors including, the prevailing market price of our common stock and the extent to which we are able to secure working capital from other sources. As of the date of issuance of this Quarterly Report on Form 10-Q, the Company has already received approximately $1.3 million from the Purchase Agreement from the sale of 296,000 shares of common stock to Lincoln Park from the inception of the Purchase Agreement through the date of issuance of this Form 10-Q, leaving the Company an additional $18.7 million to draw upon, subject to the Company’s compliance with the terms and conditions of the Purchase Agreement. Although it is difficult to predict the Company’s liquidity requirements, as of September 30, 2020, and based upon the Company’s current operating plan, the Company believes that it will have sufficient cash to meet its projected operating requirements for at least the next 12 months following the filing date of this Quarterly Report on Form 10-Q based on the balance of cash available as of September 30, 2020. The Company anticipates that it will continue to incur net losses for the foreseeable future as it continues the development of its clinical drug candidates and preclinical programs and incurs additional costs associated with being a public company.

Summary of Significant Accounti

Summary of Significant Accounting Policies	9 Months Ended
	Sep. 30, 2020
Accounting Policies [Abstract]
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	NOTE 3 Basis of Presentation The accompanying financial statements are presented in U.S. dollars and have been prepared in accordance with accounting principles generally accepted in the United States of America (“US GAAP”), and pursuant to the accounting and disclosure rules and regulations of the U.S. Securities and Exchange Commission (“SEC”). The consolidated financial statements include the accounts of INmune Bio, Inc. and its subsidiaries. Intercompany transactions and balances have been eliminated. These unaudited consolidated interim financial statements should be read in conjunction with the audited financial statements and notes thereto for the year ended December 31, 2019 included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2019, filed with the SEC on March 11, 2020. Risks and Uncertainties The Company is subject to risks and uncertainties as a result of the COVID-19 pandemic. The extent of the impact of the COVID-19 pandemic on the Company’s business is highly uncertain and difficult to predict. Also, economies worldwide have also been negatively impacted by the COVID-19 pandemic, however policymakers around the globe have responded with fiscal policy actions to support the healthcare industry and economy as a whole. The magnitude and overall effectiveness of these actions remain uncertain. In addition, the Company’s clinical trials have been affected by and may continue to be affected by the COVID-19 pandemic. Clinical site initiation and patient enrollment have and may continue to be delayed due to prioritization of hospital resources toward the COVID-19 pandemic. Some patients have not and others may not be able to comply with clinical trial protocols if quarantines impede patient movement or interrupt healthcare services. Similarly, the ability to recruit and retain patients and principal investigators and site staff who, as healthcare providers, may have heightened exposure to COVID-19, may adversely impact the Company’s clinical trial operations. The severity of the impact of the COVID-19 pandemic on the Company’s business will depend on a number of factors, including, but not limited to, the duration and severity of the pandemic and the extent and severity of the impact on the Company’s service providers, suppliers, contract research organizations (“CROs”) and the Company’s clinical trials, all of which are uncertain and cannot be predicted. As of the date of issuance of Company’s financial statements, the extent to which the COVID-19 pandemic may materially impact the Company’s financial condition, liquidity or results of operations is uncertain. Use of Estimates Preparing financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue, and expenses. Actual results and outcomes may differ from management’s estimates and assumptions. Cash and Cash Equivalents The Company considers all short-term, highly liquid investments with an original maturity at the date of purchase of three months or less to be cash equivalents. The Company maintains cash balances that may be uninsured or in deposit accounts that exceed Federal Deposit Insurance Corporation limits. The Company maintains its cash deposits with major financial institutions. Research and Development Tax Incentive Receivable The Company, through its wholly-owned subsidiary in Australia, participates in the Australian research and development tax incentive program, such that a percentage of our qualifying research and development expenditures are reimbursed by the Australian government, and such incentives are reflected as a reduction of research and development expense. The Australian research and development tax incentive is recognized when there is reasonable assurance that the incentive will be received, the relevant expenditure has been incurred and the amount of the consideration can be reliably measured. At each period end, management estimates the reimbursement available to the Company based on available information at the time. The Company, through its wholly-owned subsidiary in the United Kingdom, participates in the research and development program provided by the United Kingdom tax relief program, such that a percentage of our qualifying research and development expenditures are reimbursed by the United Kingdom government, and such incentives are reflected as a reduction of research and development expense. The United Kingdom research and development tax incentive is recognized when there is reasonable assurance that the incentive will be received, the relevant expenditure has been incurred and the amount of the consideration can be reliably measured. At each period end, management estimates the reimbursement available to the Company based on available information at the time. Intangible Assets The Company capitalizes costs incurred in connection with in-process research and development purchased from others if the asset has alternative uses and such uses are not restricted under applicable license agreements; patent applications (principally legal fees), patent purchases, and trademarks related to its cell line as intangible assets. Acquired in-process research and development costs that do not have alternative uses are expensed as incurred. Amortization is initiated for acquired in-process research and development intangible assets when their useful lives have been determined. These acquired in-process research and development intangible assets are tested at least annually or when a triggering event occurs that could indicate a potential impairment. Basic and Diluted Loss per Share Basic loss per share is computed by dividing net loss available to common shareholders by the weighted average number of outstanding common shares during the period. Diluted loss per share gives effect to all dilutive potential common shares outstanding during the period. Dilutive loss per share excludes all potential common shares if their effect is anti-dilutive. For all periods presented, there is no difference in the number of shares used to calculate basic and diluted shares outstanding due to the Company’s net loss position. At September 30, 2020, the Company had 3,457,000 potentially issuable shares of common stock upon the exercise of stock options and 1,955,922 potentially issuable shares of common stock upon the exercise of warrants. At September 30, 2019, the Company had 1,632,000 potentially issuable shares of common stock upon the exercise of stock options and 1,461,649 potentially issuable shares of common stock upon the exercise of warrants. Stock-Based Compensation The Company utilizes the Black-Scholes option pricing model to estimate the fair value of stock option awards at the date of grant, which requires the input of highly subjective assumptions, including expected volatility and expected life. Changes in these inputs and assumptions can materially affect the measure of estimated fair value of our share-based compensation. These assumptions are subjective and generally require significant analysis and judgment to develop. When estimating fair value, some of the assumptions will be based on, or determined from, external data and other assumptions may be derived from our historical experience with stock-based payment arrangements. The appropriate weight to place on historical experience is a matter of judgment, based on relevant facts and circumstances. The Company accounts for forfeitures of stock options as they occur. Research and Development Research and development (“R&D”) costs are expensed as incurred. Research and development tax incentives are recorded by the Company as a reduction of research and development costs. Major components of research and development costs include cash compensation, stock-based compensation, costs of preclinical studies, clinical trials and related clinical manufacturing, costs of drug development, costs of materials and supplies, facilities cost, overhead costs, regulatory and compliance costs, and fees paid to consultants and other entities that conduct certain research and development activities on the Company’s behalf. The Company recognizes grants as contra research and development expense in the consolidated statement of operations on a systematic basis over the periods in which the entity recognizes as expenses the related costs for which the grants are intended to compensate. Income Taxes The Company follows the liability method of accounting for income taxes. Under this method, deferred income tax assets and liabilities are recognized for the estimated tax consequences attributable to differences between the financial statement carrying values and their respective income tax basis (temporary differences). The effect on deferred income tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. On March 27, 2020, the Coronavirus Aid, Relief, and Economic Security Act, or the CARES Act, was enacted in the United States. The impact of the CARES Act on the Company for the period ending September 30, 2020 was not significant. Foreign Currency Translation The Company’s financial statements are presented in the U.S. dollar (“$”), which is the Company’s reporting currency, while its functional currencies are the U.S. Dollar for its U.S. based operations, British Pound (“GBP”) for its United Kingdom-based operations and Australian Dollars (“AUD”) for its Australian-based operations. All assets and liabilities are translated at the exchange rate on the balance sheet date, stockholders’ equity is translated at historical rates and statement of operations items are translated at the weighted average exchange rate for the period. The resulting translation adjustments are reported under other comprehensive income. Gains and losses resulting from the translations of foreign currency transactions and balances are reflected in the statement of operations and comprehensive income (loss). Recently Adopted Accounting Pronouncements There were various accounting standards and interpretations issued recently, none of which are expected to a have a material impact on the Company´s consolidated financial position, operations, or cash flows. Subsequent Events The Company evaluates events that have occurred after the balance sheet date of September 30, 2020, through the date which the financial statements are issued.

Research and Development Activi

Research and Development Activity	9 Months Ended
	Sep. 30, 2020
Research and Development [Abstract]
RESEARCH AND DEVELOPMENT ACTIVITY	NOTE 4 According to UK tax law, the Company is allowed an R&D tax incentive that reduces a company’s tax bill in the UK for expenses incurred in R&D subject to certain requirements. The Company’s UK subsidiary submits R&D tax incentive requests annually for research and development expenses incurred and recorded a related receivable in the amount of $865,228 and $395,850 as of September 30, 2020 and December 31, 2019, respectively. During the nine months ended September 30, 2020 and 2019, the Company received $0 and $152,514, respectively, of R&D tax incentive reimbursements from the UK. According to AUS tax law, the Company is allowed an R&D tax incentive that reduces a company’s tax bill in AUS for expenses incurred in R&D subject to certain requirements. The Company’s Australian subsidiary submits R&D tax incentive requests annually for research and development expenses incurred. On September 30, 2020 and December 31, 2019, the Company recorded a research and development tax incentive receivable of $600,149 and $172,289, respectively, for R&D expenses incurred in Australia. During the nine months ended September 30, 2020 and 2019, the Company received $178,029 and $0, respectively, of R&D tax incentive reimbursements from Australia. Xencor, Inc. License Agreement On October 3, 2017, the Company entered into a license agreement (“Xencor License Agreement”) with Xencor, Inc. (“Xencor”), which has discovered and developed a proprietary biological molecule that inhibits soluble tumor necrosis factor. Pursuant to the license agreement, Xencor granted the Company an exclusive worldwide, royalty-bearing license in licensed patent rights, licensed know-how and licensed materials (as defined in the license agreement) to make, develop, use, sell and import any pharmaceutical product that comprises, contains, or incorporates Xencor’s proprietary protein known as “XPro1595” that inhibits soluble tumor necrosis factor (or all modifications, formulations and variants of the licensed protein that specifically bind soluble tumor necrosis factor) alone or in combination with one or more active ingredients, in any dosage or formulation (“Licensed Products”). The Company believes the protein has numerous medical applications. Such additional alternative applications of the technology are available under the license agreement. In connection with the license agreement, the Company paid Xencor a one-time non-creditable and non-refundable fee of $100,000 and issued Xencor 1,585,000 shares of the Company’s common stock with a fair value of $12,221,000. In addition, the Company issued Xencor fully vested warrants with a fair value of $4,193,000 to purchase an additional number of shares of common stock equal to 10% of the fully diluted company shares immediately following such purchase. The warrants have an exercise price based on a valuation of the Company at $100,000,000 and expire on October 3, 2023. The aggregate purchase price for the full exercise of the option is $10,000,000 which purchase price shall be pro-rated for any partial exercise of the Warrant. In August 2018, the Company entered into a First Amendment to Stock Issuance Agreement. Pursuant to the amendment, the purchase price for the additional shares may only be paid by cash. The Company recorded $16,514,000 for the acquisition of intangible assets for the in-process research and development as the fair value of the cash, stock and warrants on the date of the License Agreement acquisition in accordance with Accounting Standards Codification 730 – Research and Development The Company also agreed to pay Xencor a royalty on Net Sales of all Licensed Products in a given calendar year, which are payable on a country-by- country and licensed product by licensed product basis until the date that is the later of (a) the expiration of the last to expire valid claim covering such Licensed Product in such country or (b) ten years following the first sale to a third party of the licensed product in such country. Under the Xencor License Agreement, the Company also agreed to pay Xencor a percentage of any sublicensing revenue that it receives. INKmune License Agreement On October 29, 2015, the Company entered into an exclusive license agreement (the “INKmune License Agreement”) with Immune Ventures, LLC (“Immune Ventures”). Pursuant to the INKmune License Agreement, the Company was granted exclusive worldwide rights to the patents, including rights to incorporate any improvements or additions to the patents that may be developed in the future. In consideration for the patent rights, the Company agreed to the following milestone payments (of which none have been met as of September 30, 2020): Each Phase I initiation $ 25,000 Each Phase II initiation $ 250,000 Each Phase III initiation $ 350,000 Each NDA/EMA filing $ 1,000,000 Each NDA/EMA awarded $ 9,000,000 In addition, the Company agreed to pay the licensor a royalty of 1% of net sales during the life of each patent granted to the Company. The License is owned by RJ Tesi, the Company’s President and a member of our Board of Directors, David Moss, its Chief Financial Officer and Treasurer and Mark Lowdell, its Chief Scientific Officer. As of September 30, 2020, no sales had occurred under this license. The term of the agreement began on October 29, 2015 and, if not terminated sooner pursuant to the agreement, ends on a country by country basis on the date of the expiration of the last to expire patent rights where patent rights exists. Upon the termination of the agreement we shall have a fully paid up, perpetual, royalty-free license without further obligation to Immune Ventures. The agreement can be terminated by Immune Ventures if, after 60 days from the Company’s receipt of notice that the Company has not made a payment under the agreement, and the Company still does not make this payment. On July 20, 2018, the parties amended the agreement under which the Company was required achieve milestones pursuant to the agreement. On October 30, 2020, the parties executed an additional amendment to the agreement under which which the Company is required to achieve the following milestones: Initiation of Phase 1 clinical or equivalent trials by October 29, 2021 Initiation of Phase II clinical trials or equivalent by October 29, 2023 Initiation of Phase III clinical trials or equivalent by October 29, 2025 Filing of NDA or equivalent by October 29, 2026 or equivalent If the Company doesn’t achieve the above milestones, it is required to negotiate in good faith with Immune Ventures to determine how it can either remedy the failure or achieve an alternate development. If the Company fails to make any required efforts, or if the efforts do not remedy the situation within 60 days of written notice by Immune Ventures, then Immune Ventures may provide notice to terminate the license or convert it to a non-exclusive license. University of Pittsburg License Agreement On October 3, 2017, the Company entered into an Assignment and Assumption Agreement with Immune Ventures related to intellectual property licensed from the University of Pittsburgh. Pursuant to the Assignment and Assumption Agreement (“Assignment Agreement”), Immune Ventures assigned all of its rights, obligations and liabilities under an Exclusive License Agreement between the University of Pittsburgh – Of the Commonwealth System of Higher Education (“Licensor”) and Immune Ventures to INmune Bio (“Licensee”), (the “PITT Agreement”). Consideration under the PITT Agreement includes: (i) annual maintenance fees, (ii) royalty payments based on the sale of products making use of the licensed technology, and (iii) milestone payments. Annual maintenance fees under the PITT Agreement include: $5,000 due June 26 of each year 2020-2022; $10,000 due on June 26 of each year 2023-2024; and $25,000 due on June 26 of each year 2025 and annually thereafter until first commercial sale. June 26 of each year 2020-2022 $ 5,000 June 26 of each year 2023-2024 $ 10,000 June 26 of each year 2025 until first commercial sale $ 25,000 Upon first commercial sale of a product making use of the licensed technology under the PITT Agreement, the Licensee is required to pay royalties equal to 2.5% of Net Sales each calendar quarter. Moreover, under the PITT Agreement the Licensee is required to make milestone payments as follows: Each Phase I initiation $ 50,000 Each Phase III initiation $ 500,000 First commercial sale of product making use of licensed technology $ 1,250,000 The Company made a $50,000 milestone payment in March 2019 pursuant to the PITT Agreement as a result of a Phase I initiation. The PITT Agreement expires upon the earlier of: (i) expiration of the last claim of the Patent Rights forming the subject matter of the PITT Agreement; or (ii) the date that is 20 years from the effective date of the agreement (June 26, 2037). Licensee may terminate the PITT Agreement upon 3 months prior written notice provided all payments under the license are current. Licensor may terminate the PITT Agreement upon written notice if: (i) Licensee defaults as to performance of material obligations which have not been cured within 60 days after receiving written notice; or (ii) Licensee ceases to carry out its business, becomes bankrupt or insolvent, applies for or consents to the appointment of a trustee, receiver or liquidator of its assets or seeks relief under any law for the aid of debtors. University College London License Agreement – MSC On July 19, 2019, the Company entered into license agreement with UCL Business PLC (“UCLB”) with a ten (10) year term. Pursuant to the license agreement, the Company acquired an exclusive license (and a right to sub-license) to the technology and know-how relating to an isolation and commercial scale expansion methodology of GMP grade human umbilical cord mesenchymal stem/stromal cells (“MSC”). In exchange for the license agreement, the Company paid UCLB an initial license fee of approximately $10,000 and shall pay annual licensing fees of approximately $13,000 per year for the remaining term of the agreement beginning in July 2020. The Company will pay UCLB a royalty of 3-3.5% of the net sales value (as defined in the agreement) of all licensed products sold or used by the Company. In the event the Company sub-licenses the technology and know-how, the Company will pay UCLB a royalty of twelve (12) percent of consideration (cash or non-cash) received by the Company in relation to the development or sub-licensing of any of the technology and know-how.

Lease

Lease	9 Months Ended
	Sep. 30, 2020
Leases [Abstract]
LEASE	NOTE 5 In May 2019, the Company signed a sublease agreement with a related party for office space in La Jolla, California, which serves as the headquarters of the Company. The lease has a 61-month term, which corresponds to the lease term of the lessor. The lessor is CTI Clinical Trial & Consulting Services (“CTI”). CTI is majority-owned by a member of the Company’s Board of Directors. The lessor may extend its lease for an additional 5 years, and, if it does, the Company may also extend its sublease for 5 years. The Company did not include the option to extend in the calculation of the lease liabilities as such extension is not reasonably certain to occur. Variable lease costs for the Company’s lease consists of operating expenses for the spaces. Below is a summary of the Company’s right-of-use assets and liabilities: December 31, 2019 September 30, 2020 Right-of-use asset – related party $ 191,543 $ 165,388 Operating lease, current liability – related party $ 8,288 $ 20,183 Long-term operating lease liability – related party 160,164 136,043 Total lease liability $ 168,452 $ 156,226 Weighted-average remaining lease term 4.5 years 3.8 years Weighted-average discount rate 10.00 % 10.00 % During the nine months ended September 30, 2020, the Company recognized $39,321 in operating lease expense, which is included in general and administrative expenses in the Company’s consolidated statement of operations.

Related Party Transactions

Related Party Transactions	9 Months Ended
	Sep. 30, 2020
Related Party Transactions [Abstract]
RELATED PARTY TRANSACTIONS	NOTE 6 UCL At September 30, 2020 and December 31, 2019, the Company owed UCL Consultants Limited (“UCL”) $9,132 and $9,379, respectively, in connection with medical research performed on behalf of the Company. During the nine months ending September 30, 2020 and 2019, the Company paid UCL $334,738 and $291,622, respectively, for medical research performed on behalf of the Company. UCL is a wholly owned subsidiary of the University of London. The Company’s Chief Scientific and Manufacturing Officer is a professor at the University of London. CTI At September 30, 2020 and December 31, 2019, the Company owed CTI $0 and $280,723, respectively, for medical research performed on behalf of the Company. During the nine months ending September 30, 2020 and 2019, the Company paid CTI $126,850 and $1,060,110, respectively, for medical research performed on behalf of the Company. During the nine months ended September 30, 2020 and 2019, the Company paid CTI $25,392 and $24,653, respectively, pursuant to its sublease agreement with CTI. See Note 5. During the nine months ended September 30, 2020, the Company recorded a capital contribution of $215,761 for the forgiveness of certain accounts payable due to CTI.

Stockholders' Equity

Stockholders' Equity	9 Months Ended
	Sep. 30, 2020
Stockholders' Equity Note [Abstract]
STOCKHOLDERS’ EQUITY	NOTE 7 Initial Public Offering During February 2019, the Company completed its initial public offering in which the Company sold 1,020,820 shares of its common stock for gross proceeds of $8,166,560 (net proceeds of $7,251,142). April and May 2019 Stock Sale During April and May 2019, the Company sold 522,212 shares of its common stock to certain investors for cash proceeds of $4,727,879, of which the Company’s CEO purchased 11,100 shares for $119,325 of cash and the Company’s CFO purchased 5,000 shares for $53,550 of cash. Lincoln Park On May 15, 2019, the Company entered into both a securities purchase agreement and registration rights agreement with Lincoln Park Capital Fund, LLC (“Lincoln Park”). Under the terms and subject to the conditions of the securities purchase agreement, the Company has the right to sell to Lincoln Park, and Lincoln Park is obligated to purchase, up to $20.0 million in shares of the Company’s common stock, subject to certain limitations, from time to time, over the 24-month period that commenced on May 15, 2019. During May 2019, the Company issued 70,000 shares of the Company’s common stock to Lincoln Park as consideration for Lincoln Park’s commitment to purchase shares of the Company’s common stock under the agreement, and 30,000 shares of common stock were sold to Lincoln Park in an initial purchase for an aggregate gross purchase price of $300,000 ($230,000 net of offering costs). During the nine months ended September 30, 2020, the Company issued 196,000 shares of its common stock to Lincoln Park for $1,002,644 of cash. At September 30, 2020, Lincoln Park is obligated to purchase up to $18.7 million worth of the Company’s common stock. As contemplated by the securities purchase agreement with Lincoln Park, and so long as the closing price of the Company’s common stock exceeds $3.50 per share, then the Company may, subject to the terms and conditions of the Agreement, direct Lincoln Park, at its sole discretion to purchase up to 20,000 shares of its common stock on any business day. The purchase price will be based on the market prices of the common stock at the time of such purchases as set forth in the securities purchase agreement. In addition to regular purchases, the Company may, subject to the terms and conditions of the Agreement, also direct Lincoln Park to purchase other amounts as accelerated purchases or as additional purchases if the closing sale price of the common stock exceeds certain threshold prices as set forth in the purchase agreement. There are no trading volume requirements or restrictions under the purchase agreement nor any upper limits on the price per share that Lincoln Park must pay for shares of common stock. Purchase and retirement of common stock During January 2020, the Company purchased and cancelled 220,000 shares of its common stock from a shareholder in exchange for $1,012,000 of cash. Immediately following the purchase, the investor owned less than 10% of the outstanding common stock of the Company. Common Stock – At the Market Offering During April 2020, the Company entered into a sales agreement with BTIG, LLC (“BTIG”), as sales agent, to establish an At-The-Market (“ATM”) offering program. The sales agreement with BTIG was subsequently amended during August 2020. The Company was required to pay BTIG a commission of 3% of the gross proceeds from the sale of shares. The ATM program will remain in full force and effect until the earlier of the sale of all of the shares under the ATM program or the termination of the sales agreement by the Company or BTIG. From the inception of the agreement through September 30, 2020, the Company sold 178,600 shares of common stock at an average price of $5.45 per share for gross proceeds of $972,879 (net proceeds of $812,828), of which 150,682 shares were sold for gross proceeds of $820,319 (net proceeds $664,845) during the three months ended June 30, 2020 and 27,918 shares were sold for gross proceeds of $152,560 (net proceeds of $147,983) during the three months ended September 30, 2020. Pursuant to the ATM, the Company paid BTIG commissions and fees of $74,610 during the three months ended June 30, 2020 and $4,577 during the three months ended September 30, 2020. Underwritten Stock Offering During July 2020, the Company completed an underwritten public offering in which it sold 2,500,000 shares of common stock at a public offering price of $10.00 per share. The 2,500,000 shares sold included the full exercise of the underwriters’ option to purchase 326,086 shares at a price of $10.00 per share. Aggregate net proceeds from the underwritten public offering were $23.1 million, net of approximately $1.9 million in underwriting discounts and commissions and offering expenses. Common Stock Issued for Services During July 2020, the Company granted a consultant 50,000 fully vested warrants with a 5-year term, of which 25,000 warrants had an exercise price of $5.50 per share and 25,000 warrants had an exercise price of $10.00 per share. The fair value of these warrants was $356,874 based on the Black-Scholes Option Pricing Model and was recorded within general and administrative expense. The assumptions used for these warrants consist of the exercise prices, expected dividends of 0%, expected volatility of 111.67% based on the trading history of similar companies, risk-free rate of 0.30% based on the applicable US Treasury bill rate and an expected life of 5.0 years. During July 2020, the Company issued the consultant 20,000 shares of common stock and cancelled the 50,000 warrants. The 20,000 shares were issued from the Company’s 2019 Incentive Stock Plan and had a fair value of approximately $230,000 based on the market value of the Company’s common stock on the grant date. The Company accounted for the exchange of the warrants for shares of common stock as a modification and recorded no additional expense in connection with the exchange as the fair value of warrants exceeded the fair value of the shares issued. Common Stock Issuable Pacific Seaboard Consulting Agreement On May 16, 2018, the Company entered into a consulting agreement with Pacific Seaboard Investments Ltd. (“Pacific Seaboard”) for corporate governance, compliance services regarding the filing of a listing application and assist with activities related to its initial public offering. In consideration of the consultant’s services, the Company agreed to issue 600,000 shares of its restricted common stock. Pursuant to this agreement, the Company recorded $4,626,000 as common stock issuable for the 600,000 shares of common stock to be issued. During June 2019, the Company issued 400,000 shares of its common stock to Pacific Seaboard, whereby the Company was initially required to issue 600,000 shares to Pacific Seaboard, but subsequently received a waiver from Pacific Seaboard during April 2019 permanently waiving the last 200,000 shares owed. Settlement In November 2016, the Company entered into a settlement agreement whereby the Company agreed to issue 33,335 shares of the Company’s common stock to an individual to settle a claim in full. The Company assessed the value of the common stock owed form the most readily determinable value of the shares of the Company’s common stock issuable as a part of this settlement. These shares have not been issued and are subject to a restriction on transfer for a period of two years from the date the Company completed its initial public offering, which occurred during February 2019, after which the Company will deliver the shares to the individual. The obligation was recorded as common stock issuable of $50,000 as of September 30, 2020 and December 31, 2019, respectively, pending delivery of the shares to the individual after the restriction period expires. Stock options During September 2020, the Company granted an employee options to purchase 40,000 shares of its common stock pursuant to the 2019 Incentive Stock Plan. The stock options have a fair value of $339,731 that was calculated using the Black-Scholes option-pricing model. Variables used in the Black-Scholes option-pricing model include: (1) discount rate of 0.46% based on the applicable US Treasury bill rate (2) expected life of 6.25 years, (3) expected volatility of approximately 106% based on the trading history of similar companies, and (4) zero expected dividends. The following table summarizes stock option activity during the nine months ended September 30, 2020: Number of Shares Weighted- average Exercise Price Weighted-average Remaining Contractual Term (years) Aggregate Intrinsic Value Outstanding at January 1, 2020 3,417,000 $ 5.77 9.03 - Options granted 40,000 $ 10.38 - - Options exercised - $ - - - Options cancelled - $ - - - Outstanding at September 30, 2020 3,457,000 $ 5.82 8.30 $ 15,520,320 Exercisable at September 30, 2020 1,989,931 $ 6.96 7.71 $ 6,667,156 During the nine months ended September 30, 2020 and 2019, the Company recognized stock-based compensation expense of $2,052,192 and $2,924,091, respectively, related to stock options. As of September 30, 2020, there was $4,780,427 of total unrecognized compensation cost related to non-vested stock options which is expected to be recognized over a weighted-average period of 2.17 years. Warrants In connection with the Company’s initial public offering in February 2019, the Company issued warrants to the placement agents to purchase 40,982 shares of the Company’s common stock at an exercise price of $9.60 per common share, which warrants are exercisable until December 19, 2023. During July 2020, 6,147 of these warrants were exercised on a cashless basis in exchange for 2,400 shares of the Company’s common stock. At September 30, 2020, 34,835 of these warrants are outstanding and the intrinsic value is $24,733. In October 2017, in connection with the Xencor License Agreement, the Company issued fully vested warrants to purchase an additional number of shares of common stock equal to 10% of the fully diluted Company shares immediately following such purchase. See Note 4. These warrants had an intrinsic value of $9,479,920 as of September 30, 2020. On June 30, 2017, the Company issued fully vested warrants with a maturity date of June 30, 2022 and an exercise price of $1.50 to purchase 31,667 shares of the Company’s common stock to a third party in conjunction with common stock sold for cash. These warrants had an intrinsic value of $278,986 as of September 30, 2020. Stock-based Compensation by Class of Expense The following summarizes the components of stock-based compensation expense in the consolidated statements of operations for the three and nine months ended September 30, 2020 and 2019 respectively: Three Months Ended Three Months Ended Nine Months Ended Nine Months Ended Research and development $ 145,687 $ 426,308 $ 422,905 $ 1,278,924 General and administrative 899,969 548,388 1,986,161 1,645,167 Total $ 1,045,656 $ 974,696 $ 2,409,066 $ 2,924,091

Collaborative Agreements

Collaborative Agreements	9 Months Ended
	Sep. 30, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]
COLLABORATIVE AGREEMENTS	NOTE 8 During 2019, the Company was awarded a $1,000,000 grant from the Alzheimer’s Association to advance XPro1595, a novel therapy targeting neuroinflammation as a cause of Alzheimer’s disease. The endowment was awarded under the Part the Cloud to RESCUE grant. During the nine months ending September 30, 2020 and 2019, the Company received $150,000 and $600,000, respectively, related to the grant, which the Company recorded as a reduction of research and development expense. As of September 30, 2020, the Company has received $1,000,000 of cash proceeds from the Alzheimer’s Association and no additional amounts are available to the Company pursuant to this grant. During the nine months ended September 30, 2020, the Company was awarded a $500,000 grant from the Amyotrophic Lateral Sclerosis (“ALS”) Association to fund a study of the efficacy of XPro1595 to reverse ALS in vitro and to fund a study of the efficacy of XPro1595 to protect against ALS model phenotypes in vivo. During the nine months ended September 30, 2020, the Company received $300,000 of cash proceeds pursuant to this grant which the Company recorded as deferred liabilities. During the three and nine months ended September 30, 2020, the Company recorded $110,878 as a reduction of deferred liabilities as a result of incurring costs related to the ALS grant. As of September 30, 2020, the Company recorded $189,122 as deferred liabilities in the consolidated balance sheet related to the ALS grant. During September 2020, the Company was awarded a grant of up to $2.9 million from the National Institutes of Health (NIH), of which the Company expects to receive approximately $0.7 million in 2020, approximately $1.2 million in 20201 and approximately $1.0 million in 2022. The grant will support a Phase 2 study of XPro1595 in patients with treatment resistant depression. As of September 30, 2020, the Company has not received any proceeds pursuant to this grant.

Accounting Policies, by Policy

Accounting Policies, by Policy (Policies)	9 Months Ended
	Sep. 30, 2020
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation The accompanying financial statements are presented in U.S. dollars and have been prepared in accordance with accounting principles generally accepted in the United States of America (“US GAAP”), and pursuant to the accounting and disclosure rules and regulations of the U.S. Securities and Exchange Commission (“SEC”). The consolidated financial statements include the accounts of INmune Bio, Inc. and its subsidiaries. Intercompany transactions and balances have been eliminated. These unaudited consolidated interim financial statements should be read in conjunction with the audited financial statements and notes thereto for the year ended December 31, 2019 included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2019, filed with the SEC on March 11, 2020.
Risks and Uncertainties	Risks and Uncertainties The Company is subject to risks and uncertainties as a result of the COVID-19 pandemic. The extent of the impact of the COVID-19 pandemic on the Company’s business is highly uncertain and difficult to predict. Also, economies worldwide have also been negatively impacted by the COVID-19 pandemic, however policymakers around the globe have responded with fiscal policy actions to support the healthcare industry and economy as a whole. The magnitude and overall effectiveness of these actions remain uncertain. In addition, the Company’s clinical trials have been affected by and may continue to be affected by the COVID-19 pandemic. Clinical site initiation and patient enrollment have and may continue to be delayed due to prioritization of hospital resources toward the COVID-19 pandemic. Some patients have not and others may not be able to comply with clinical trial protocols if quarantines impede patient movement or interrupt healthcare services. Similarly, the ability to recruit and retain patients and principal investigators and site staff who, as healthcare providers, may have heightened exposure to COVID-19, may adversely impact the Company’s clinical trial operations. The severity of the impact of the COVID-19 pandemic on the Company’s business will depend on a number of factors, including, but not limited to, the duration and severity of the pandemic and the extent and severity of the impact on the Company’s service providers, suppliers, contract research organizations (“CROs”) and the Company’s clinical trials, all of which are uncertain and cannot be predicted. As of the date of issuance of Company’s financial statements, the extent to which the COVID-19 pandemic may materially impact the Company’s financial condition, liquidity or results of operations is uncertain.
Use of Estimates	Use of Estimates Preparing financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue, and expenses. Actual results and outcomes may differ from management’s estimates and assumptions.
Cash and Cash Equivalents	Cash and Cash Equivalents The Company considers all short-term, highly liquid investments with an original maturity at the date of purchase of three months or less to be cash equivalents. The Company maintains cash balances that may be uninsured or in deposit accounts that exceed Federal Deposit Insurance Corporation limits. The Company maintains its cash deposits with major financial institutions.
Research and Development Tax Incentive Receivable	Research and Development Tax Incentive Receivable The Company, through its wholly-owned subsidiary in Australia, participates in the Australian research and development tax incentive program, such that a percentage of our qualifying research and development expenditures are reimbursed by the Australian government, and such incentives are reflected as a reduction of research and development expense. The Australian research and development tax incentive is recognized when there is reasonable assurance that the incentive will be received, the relevant expenditure has been incurred and the amount of the consideration can be reliably measured. At each period end, management estimates the reimbursement available to the Company based on available information at the time. The Company, through its wholly-owned subsidiary in the United Kingdom, participates in the research and development program provided by the United Kingdom tax relief program, such that a percentage of our qualifying research and development expenditures are reimbursed by the United Kingdom government, and such incentives are reflected as a reduction of research and development expense. The United Kingdom research and development tax incentive is recognized when there is reasonable assurance that the incentive will be received, the relevant expenditure has been incurred and the amount of the consideration can be reliably measured. At each period end, management estimates the reimbursement available to the Company based on available information at the time.
Intangible Assets	Intangible Assets The Company capitalizes costs incurred in connection with in-process research and development purchased from others if the asset has alternative uses and such uses are not restricted under applicable license agreements; patent applications (principally legal fees), patent purchases, and trademarks related to its cell line as intangible assets. Acquired in-process research and development costs that do not have alternative uses are expensed as incurred. Amortization is initiated for acquired in-process research and development intangible assets when their useful lives have been determined. These acquired in-process research and development intangible assets are tested at least annually or when a triggering event occurs that could indicate a potential impairment.
Basic and Diluted Loss per Share	Basic and Diluted Loss per Share Basic loss per share is computed by dividing net loss available to common shareholders by the weighted average number of outstanding common shares during the period. Diluted loss per share gives effect to all dilutive potential common shares outstanding during the period. Dilutive loss per share excludes all potential common shares if their effect is anti-dilutive. For all periods presented, there is no difference in the number of shares used to calculate basic and diluted shares outstanding due to the Company’s net loss position. At September 30, 2020, the Company had 3,457,000 potentially issuable shares of common stock upon the exercise of stock options and 1,955,922 potentially issuable shares of common stock upon the exercise of warrants. At September 30, 2019, the Company had 1,632,000 potentially issuable shares of common stock upon the exercise of stock options and 1,461,649 potentially issuable shares of common stock upon the exercise of warrants.
Stock-Based Compensation	Stock-Based Compensation The Company utilizes the Black-Scholes option pricing model to estimate the fair value of stock option awards at the date of grant, which requires the input of highly subjective assumptions, including expected volatility and expected life. Changes in these inputs and assumptions can materially affect the measure of estimated fair value of our share-based compensation. These assumptions are subjective and generally require significant analysis and judgment to develop. When estimating fair value, some of the assumptions will be based on, or determined from, external data and other assumptions may be derived from our historical experience with stock-based payment arrangements. The appropriate weight to place on historical experience is a matter of judgment, based on relevant facts and circumstances. The Company accounts for forfeitures of stock options as they occur.
Research and Development	Research and Development Research and development (“R&D”) costs are expensed as incurred. Research and development tax incentives are recorded by the Company as a reduction of research and development costs. Major components of research and development costs include cash compensation, stock-based compensation, costs of preclinical studies, clinical trials and related clinical manufacturing, costs of drug development, costs of materials and supplies, facilities cost, overhead costs, regulatory and compliance costs, and fees paid to consultants and other entities that conduct certain research and development activities on the Company’s behalf. The Company recognizes grants as contra research and development expense in the consolidated statement of operations on a systematic basis over the periods in which the entity recognizes as expenses the related costs for which the grants are intended to compensate.
Income Taxes	Income Taxes The Company follows the liability method of accounting for income taxes. Under this method, deferred income tax assets and liabilities are recognized for the estimated tax consequences attributable to differences between the financial statement carrying values and their respective income tax basis (temporary differences). The effect on deferred income tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. On March 27, 2020, the Coronavirus Aid, Relief, and Economic Security Act, or the CARES Act, was enacted in the United States. The impact of the CARES Act on the Company for the period ending September 30, 2020 was not significant.
Foreign Currency Translation	Foreign Currency Translation The Company’s financial statements are presented in the U.S. dollar (“$”), which is the Company’s reporting currency, while its functional currencies are the U.S. Dollar for its U.S. based operations, British Pound (“GBP”) for its United Kingdom-based operations and Australian Dollars (“AUD”) for its Australian-based operations. All assets and liabilities are translated at the exchange rate on the balance sheet date, stockholders’ equity is translated at historical rates and statement of operations items are translated at the weighted average exchange rate for the period. The resulting translation adjustments are reported under other comprehensive income. Gains and losses resulting from the translations of foreign currency transactions and balances are reflected in the statement of operations and comprehensive income (loss).
Recently Adopted Accounting Pronouncements	Recently Adopted Accounting Pronouncements There were various accounting standards and interpretations issued recently, none of which are expected to a have a material impact on the Company´s consolidated financial position, operations, or cash flows.
Subsequent Events	Subsequent Events The Company evaluates events that have occurred after the balance sheet date of September 30, 2020, through the date which the financial statements are issued.

Research and Development Acti_2

Research and Development Activity (Tables)	9 Months Ended
	Sep. 30, 2020
Research and Development [Abstract]
Schedule of milestone payments in consideration for the patent rights	Each Phase I initiation $ 25,000 Each Phase II initiation $ 250,000 Each Phase III initiation $ 350,000 Each NDA/EMA filing $ 1,000,000 Each NDA/EMA awarded $ 9,000,000
Schedule of consideration of annual maintenance fees under the PITT agreement	June 26 of each year 2020-2022 $ 5,000 June 26 of each year 2023-2024 $ 10,000 June 26 of each year 2025 until first commercial sale $ 25,000
Schedule of licensee required to make milestone payments	Each Phase I initiation $ 50,000 Each Phase III initiation $ 500,000 First commercial sale of product making use of licensed technology $ 1,250,000

Lease (Tables)

Lease (Tables)	9 Months Ended
	Sep. 30, 2020
Leases [Abstract]
Schedule of right-of-use assets and liabilities for operating lease	December 31, 2019 September 30, 2020 Right-of-use asset – related party $ 191,543 $ 165,388 Operating lease, current liability – related party $ 8,288 $ 20,183 Long-term operating lease liability – related party 160,164 136,043 Total lease liability $ 168,452 $ 156,226 Weighted-average remaining lease term 4.5 years 3.8 years Weighted-average discount rate 10.00 % 10.00 %

Stockholders' Equity (Tables)

Stockholders' Equity (Tables)	9 Months Ended
	Sep. 30, 2020
Stockholders' Equity Note [Abstract]
Schedule of stock option activity	Number of Shares Weighted- average Exercise Price Weighted-average Remaining Contractual Term (years) Aggregate Intrinsic Value Outstanding at January 1, 2020 3,417,000 $ 5.77 9.03 - Options granted 40,000 $ 10.38 - - Options exercised - $ - - - Options cancelled - $ - - - Outstanding at September 30, 2020 3,457,000 $ 5.82 8.30 $ 15,520,320 Exercisable at September 30, 2020 1,989,931 $ 6.96 7.71 $ 6,667,156
Schedule of stock-based compensation expense	Three Months Ended Three Months Ended Nine Months Ended Nine Months Ended Research and development $ 145,687 $ 426,308 $ 422,905 $ 1,278,924 General and administrative 899,969 548,388 1,986,161 1,645,167 Total $ 1,045,656 $ 974,696 $ 2,409,066 $ 2,924,091

Liquidity (Details)

Liquidity (Details) - USD ($)	1 Months Ended			2 Months Ended	6 Months Ended	9 Months Ended
	Jul. 31, 2020	Apr. 30, 2020	May 31, 2019	May 31, 2019	Sep. 30, 2020	Sep. 30, 2020	Dec. 31, 2019
Liquidity (Details) [Line Items]
Accumulated deficit					$ (30,171,054)	$ (30,171,054)	$ (21,276,181)
Sale of common stock shares	2,500,000			522,212		196,000
Public offering price, per share	$ 10
Option to purchase shares	326,086
Purchase agreement, description			the Company entered into a securities purchase agreement (“Purchase Agreement”) with Lincoln Park Capital Fund LLC (“Lincoln Park”), pursuant to which Lincoln Park has agreed to purchase from the Company up to an aggregate of $20.0 million of common stock of the Company (subject to certain limitations) from time to time over the term of the Purchase Agreement. The extent we rely on Lincoln Park as a source of funding will depend on a number of factors including, the prevailing market price of our common stock and the extent to which we are able to secure working capital from other sources. As of the date of issuance of this Quarterly Report on Form 10-Q, the Company has already received approximately $1.3 million from the Purchase Agreement from the sale of 296,000 shares of common stock to Lincoln Park from the inception of the Purchase Agreement through the date of issuance of this Form 10-Q, leaving the Company an additional $18.7 million to draw upon
Initial Public Offering [Member]
Liquidity (Details) [Line Items]
Sale of common stock shares	2,500,000
Public offering price, per share	$ 10
Aggregate offering price	$ 23,100,000
Underwriting expenses	$ 1,900,000
ATM Sales Agreement [Member]
Liquidity (Details) [Line Items]
Sale of common stock shares					178,600
Gross proceeds from the sale of shares, percentage		3.00%
Price, per share					$ 5.45	$ 5.45
Net proceeds under ATM offering					$ 800,000

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Details) - shares	9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019
Accounting Policies [Abstract]
Potentially issuable shares of common stock upon the exercise of stock options	3,457,000	1,632,000
Potentially issuable shares of common stock upon the exercise of warrants	1,955,922	1,461,649

Research and Development Acti_3

Research and Development Activity (Details) - USD ($)	1 Months Ended		3 Months Ended	9 Months Ended		12 Months Ended
	Jul. 19, 2019	Oct. 03, 2017	Mar. 31, 2019	Sep. 30, 2020	Sep. 30, 2019	Dec. 31, 2019	Oct. 29, 2015
Research and Development Activity (Details) [Line Items]
Common stock issued (in Shares)				13,447,948		10,770,948
Expiry date of warrants exercise price based on a valuation		October 3, 2023
License agreement, term	10 years
License fee, description				In exchange for the license agreement, the Company paid UCLB an initial license fee of approximately $10,000 and shall pay annual licensing fees of approximately $13,000 per year for the remaining term of the agreement beginning in July 2020. The Company will pay UCLB a royalty of 3-3.5% of the net sales value (as defined in the agreement) of all licensed products sold or used by the Company. In the event the Company sub-licenses the technology and know-how, the Company will pay UCLB a royalty of twelve (12) percent of consideration (cash or non-cash) received by the Company in relation to the development or sub-licensing of any of the technology and know-how.
Research and Development Expense [Member] | UNITED KINGDOM
Research and Development Activity (Details) [Line Items]
Research and development tax credit receivable				$ 865,228		$ 395,850
Reimbursements of research and development tax credit				0	$ 152,514
Research and Development Expense [Member] | AUSTRALIA
Research and Development Activity (Details) [Line Items]
Research and development tax credit receivable				600,149		$ 172,289
Reimbursements of research and development tax credit				178,029	$ 0
Xencor, Inc. License Agreement [Member]
Research and Development Activity (Details) [Line Items]
Non refundable fee		$ 100,000
Common stock issued (in Shares)		1,585,000
Common stock with fair value on discounted cash flow		$ 12,221,000
Fair value of warrants		$ 4,193,000
Common stock equal to fully diluted shares to purchase with fair value		10.00%
Warrant exercise price based on valuation of the company		$ 100,000,000
Aggregate purchase price for exercise of option pro-rated for any partial exercise		$ 10,000,000
In-process research and development				16,514,000
Inkmune License Agreement [Member]
Research and Development Activity (Details) [Line Items]
Percentage of licensor royalty patent grant							1.00%
University of Pittsburg License Agreement [Member]
Research and Development Activity (Details) [Line Items]
Percentage of net sales to pay royalties		2.50%
University of Pittsburg License Agreement [Member] | Annual Maintenance Fees [Member] | June 26 of each year 2020-2022 [Member]
Research and Development Activity (Details) [Line Items]
Long-term commercial paper				5,000
University of Pittsburg License Agreement [Member] | Annual Maintenance Fees [Member] | June 26 of each year 2023-2024 [Member]
Research and Development Activity (Details) [Line Items]
Long-term commercial paper				10,000
University of Pittsburg License Agreement [Member] | Annual Maintenance Fees [Member] | June 26 of each year 2025 until first commercial sale [Member]
Research and Development Activity (Details) [Line Items]
Long-term commercial paper				$ 25,000
Immune Ventures to Inmune Bio [Member]
Research and Development Activity (Details) [Line Items]
Agreement expiry period, description				PITT Agreement expires upon the earlier of: (i) expiration of the last claim of the Patent Rights forming the subject matter of the PITT Agreement; or (ii) the date that is 20 years from the effective date of the agreement (June 26, 2037).
Each Phase I initiation [Member] | Immune Ventures to Inmune Bio [Member]
Research and Development Activity (Details) [Line Items]
Payment method of milestone payments			$ 50,000	$ 50,000

Research and Development Acti_4

Research and Development Activity (Details) - Schedule of milestone payments in consideration for the patent rights - Inkmune License Agreement [Member] - Immune Ventures LLc [Member] - Patents [Member]	9 Months Ended
	Sep. 30, 2020USD ($)
Each Phase I initiation [Member]
Research and Development Activity (Details) - Schedule of milestone payments in consideration for the patent rights [Line Items]
Payment method of milestone payments	$ 25,000
Each Phase II initiation [Member]
Research and Development Activity (Details) - Schedule of milestone payments in consideration for the patent rights [Line Items]
Payment method of milestone payments	250,000
Each Phase III initiation [Member]
Research and Development Activity (Details) - Schedule of milestone payments in consideration for the patent rights [Line Items]
Payment method of milestone payments	350,000
Each NDA/EMA filing [Member]
Research and Development Activity (Details) - Schedule of milestone payments in consideration for the patent rights [Line Items]
Payment method of milestone payments	1,000,000
Each NDA/EMA awarded [Member]
Research and Development Activity (Details) - Schedule of milestone payments in consideration for the patent rights [Line Items]
Payment method of milestone payments	$ 9,000,000

Research and Development Acti_5

Research and Development Activity (Details) - Schedule of consideration of annual maintenance fees under the PITT agreement - University of Pittsburg License Agreement [Member] - Annual Maintenance Fees [Member]	Sep. 30, 2020USD ($)
June 26 of each year 2020-2022 [Member]
Research and Development Activity (Details) - Schedule of consideration of annual maintenance fees under the PITT agreement [Line Items]
Annual maintenance fees until first commercial sale	$ 5,000
June 26 of each year 2023-2024 [Member]
Research and Development Activity (Details) - Schedule of consideration of annual maintenance fees under the PITT agreement [Line Items]
Annual maintenance fees until first commercial sale	10,000
June 26 of each year 2025 until first commercial sale [Member]
Research and Development Activity (Details) - Schedule of consideration of annual maintenance fees under the PITT agreement [Line Items]
Annual maintenance fees until first commercial sale	$ 25,000

Research and Development Acti_6

Research and Development Activity (Details) - Schedule of licensee required to make milestone payments - Immune Ventures to Inmune Bio [Member] - USD ($)	3 Months Ended	9 Months Ended
	Mar. 31, 2019	Sep. 30, 2020
Each Phase I initiation [Member]
Research and Development Activity (Details) - Schedule of licensee required to make milestone payments [Line Items]
Payment method of milestone payments	$ 50,000	$ 50,000
Each Phase III initiation [Member]
Research and Development Activity (Details) - Schedule of licensee required to make milestone payments [Line Items]
Payment method of milestone payments		500,000
First commercial sale of product making use of licensed technology [Member]
Research and Development Activity (Details) - Schedule of licensee required to make milestone payments [Line Items]
Payment method of milestone payments		$ 1,250,000

Lease (Details)

Lease (Details)	1 Months Ended
	May 31, 2020USD ($)
Lease (Details) [Line Items]
Lease term	61 months
Description of extend lease term	The lessor may extend its lease for an additional 5 years, and, if it does, the Company may also extend its sublease for 5 years.
General and Administrative [Member]
Lease (Details) [Line Items]
General and administrative expenses	$ 39,321

Lease (Details) - Schedule of r

Lease (Details) - Schedule of right-of-use assets and liabilities for operating lease - USD ($)	Sep. 30, 2020	Dec. 31, 2019
Schedule of right-of-use assets and liabilities for operating lease [Abstract]
Right-of-use asset – related party	$ 165,388	$ 191,543
Operating lease, current liability – related party	20,183	8,288
Long-term operating lease liability – related party	136,043	160,164
Total lease liability	$ 156,226	$ 168,452
Weighted-average remaining lease term	3 years 292 days	4 years 6 months
Weighted-average discount rate	10.00%	10.00%

Related Party Transactions (Det

Related Party Transactions (Details) - USD ($)	9 Months Ended	12 Months Ended
	Sep. 30, 2020	Dec. 31, 2019
UCL Consultants Limited [Member]
Related Party Transactions (Details) [Line Items]
Amount of company owed to UCL Consultants Limited	$ 9,132	$ 9,379
Payment for medical research performed expense	334,738	291,622
Clinical Trial and Consulting Services [Member]
Related Party Transactions (Details) [Line Items]
Amount of company owed to UCL Consultants Limited	0	280,723
Payment for medical research performed expense	126,850	1,060,110
Capital contribution	215,761
Clinical Trial and Consulting Services [Member] | Sublease Agreement [Member]
Related Party Transactions (Details) [Line Items]
Amount paid for sublease agreement	$ 25,392	$ 24,653

Stockholders' Equity (Details)

Stockholders' Equity (Details) - USD ($)	May 15, 2019	Jul. 31, 2020	Apr. 30, 2020	Jan. 31, 2020	Jun. 30, 2019	May 31, 2019	Apr. 30, 2019	Feb. 28, 2019	May 16, 2018	Nov. 30, 2016	May 31, 2019	Sep. 30, 2020	Jun. 30, 2020	Sep. 30, 2020	Sep. 30, 2020	Sep. 30, 2019	Jun. 30, 2017
Stockholders' Equity (Details) [Line Items]
Number of common stock sold (in Shares)		2,500,000									522,212				196,000
Gross proceeds from common stock sold															$ 18,700,000
Net proceeds from common stock sold				$ 220,000							$ 4,727,879
Number of shares issuance (in Shares)						70,000
Value of shares issuance															$ 1,002,644
Securities purchase agreement						$ 300,000					300,000
Shareholder in exchange				$ 1,012,000
Stock options discount rate				10.00%
Public offering price, per share (in Dollars per share)		$ 10
Option to purchase shares (in Shares)		326,086
Warrant, description		the Company granted a consultant 50,000 fully vested warrants with a 5-year term, of which 25,000 warrants had an exercise price of $5.50 per share and 25,000 warrants had an exercise price of $10.00 per share.
Number of share waive off to issued (in Shares)							200,000
Settlement agreement,description										the Company entered into a settlement agreement whereby the Company agreed to issue 33,335 shares of the Company’s common stock to an individual to settle a claim in full. The Company assessed the value of the common stock owed form the most readily determinable value of the shares of the Company’s common stock issuable as a part of this settlement. These shares have not been issued and are subject to a restriction on transfer for a period of two years from the date the Company completed its initial public offering, which occurred during February 2019, after which the Company will deliver the shares to the individual. The obligation was recorded as common stock issuable of $50,000 as of September 30, 2020 and December 31, 2019, respectively, pending delivery of the shares to the individual after the restriction period expires.
Warrant Exchange description															During July 2020, 6,147 of these warrants were exercised on a cashless basis in exchange for 2,400 shares of the Company’s common stock.
Warrants intrinsic value															$ 9,479,920
Warrant [Member]
Stockholders' Equity (Details) [Line Items]
Warrant, description		the Company issued the consultant 20,000 shares of common stock and cancelled the 50,000 warrants. The 20,000 shares were issued from the Company’s 2019 Incentive Stock Plan and had a fair value of approximately $230,000 based on the market value of the Company’s common stock on the grant date.
Fair value of warrants		$ 356,874
Expected dividends		0.00%
Expected volatility		111.67%
Risk-free rate		0.30%
Expected life		5 years
Exercise price of warrants (in Dollars per share)																	$ 1.50
Warrants are outstanding (in Shares)												34,835		34,835	34,835
Intrinsic value of warrant												$ 24,733		$ 24,733	$ 24,733		$ 278,986
Number of fully vested warrants issued (in Shares)																	31,667
Lincoln Park Purchase Agreement [Member] | Common Stock [Member]
Stockholders' Equity (Details) [Line Items]
Number of common stock sold (in Shares)						30,000
Right but not the obligation to sell additional shares	$ 20,000,000
Net of offering costs						$ 230,000					$ 230,000
Threshold closing price of common stock (in Dollars per share)	$ 3.50
Maximum number of share sold in single business day (in Shares)	20,000
ATM Sales Agreement [Member]
Stockholders' Equity (Details) [Line Items]
Number of common stock sold (in Shares)												27,918	150,682	178,600
Gross proceeds from common stock sold												$ 152,560	$ 820,319	$ 972,879
Gross proceeds from the sale of shares, percentage			3.00%
Price, per share (in Dollars per share)												$ 5.45		$ 5.45	$ 5.45
Net proceeds under ATM offering												$ 147,983	664,845	$ 812,828
commissions and fees												$ 4,577	$ 74,610
Pacific Seaboard Investments Ltd [Member] | Common Stock [Member]
Stockholders' Equity (Details) [Line Items]
Number of common stock sold (in Shares)															600,000
Value of shares issued for consideration															$ 4,626,000
Share-based Payment Arrangement, Option [Member]
Stockholders' Equity (Details) [Line Items]
Stock options discount rate															0.46%
Expected volatility															106.00%
Expected life															6 years 3 months
Purchase of common stock (in Shares)															40,000
Aggregated fair value of stock options (in Shares)												339,731		339,731	339,731
Stock options expected dividends															$ 0
Adjustments to additional paid in capital, share-based compensation, requisite service period recognition												$ 2,052,192		$ 2,052,192	2,052,192	$ 2,924,091
Total unrecognized compensation cost related to non-vested stock												$ 4,780,427		$ 4,780,427	$ 4,780,427
Unrecognized compensation weighted-average period related to non-vested stock															2 years 62 days
IPO [Member]
Stockholders' Equity (Details) [Line Items]
Number of common stock sold (in Shares)		2,500,000						1,020,820
Gross proceeds from common stock sold								$ 8,166,560
Net proceeds from common stock sold								$ 7,251,142
Net proceeds under ATM offering		$ 23,100,000
Public offering price, per share (in Dollars per share)		$ 10
Underwriting expenses		$ 1,900,000
Number of warrants issued (in Shares)								40,982
Exercise price of warrants (in Dollars per share)								$ 9.60
Chief Executive Officer [Member]
Stockholders' Equity (Details) [Line Items]
Number of shares issuance (in Shares)											11,100
Value of shares issuance											$ 119,325
Chief Executive Officer 1 [Member]
Stockholders' Equity (Details) [Line Items]
Number of shares issuance (in Shares)											5,000
Value of shares issuance											$ 53,550
Pacific Seaboard Investments Ltd [Member]
Stockholders' Equity (Details) [Line Items]
Number of common stock sold (in Shares)									600,000
Pacific Seaboard Investments Ltd [Member] | Consulting Agreement [Member]
Stockholders' Equity (Details) [Line Items]
Number of common stock sold (in Shares)					600,000
Number of shares issued for consideration (in Shares)					400,000

Stockholders' Equity (Details)

Stockholders' Equity (Details) - Schedule of stock option activity - USD ($)	9 Months Ended
	Sep. 30, 2020
Schedule of stock option activity [Abstract]
Number of shares, Outstanding	3,417,000
Weighted- average Exercise Price, Outstanding	$ 5.77
Weighted-average Remaining Contractual Term (years), Outstanding	9 years 10 days
Number of shares, Options granted	40,000
Weighted- average Exercise Price, Options granted	$ 10.38
Number of shares, Options exercised
Weighted- average Exercise Price, Options exercised
Number of shares, Options cancelled
Weighted- average Exercise Price, Options cancelled
Number of shares, Outstanding	3,457,000
Weighted- average Exercise Price, Outstanding	$ 5.82
Weighted-average Remaining Contractual Term (years), Outstanding	8 years 109 days
Aggregate Intrinsic Value, Outstanding	$ 15,520,320
Number of shares, Exercisable at September 30, 2020	1,989,931
Weighted- average Exercise Price, Exercisable at September 30, 2020	$ 6.96
Weighted-average Remaining Contractual Term (years), Exercisable at September 30, 2020	7 years 259 days
Aggregate Intrinsic Value, Exercisable at September 30, 2020	$ 6,667,156

Stockholders' Equity (Details_2

Stockholders' Equity (Details) - Schedule of stock-based compensation expense - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Stockholders' Equity (Details) - Schedule of stock-based compensation expense [Line Items]
Total	$ 1,045,656	$ 974,696	$ 2,409,066	$ 2,924,091
Research and development [Member]
Stockholders' Equity (Details) - Schedule of stock-based compensation expense [Line Items]
Total	145,687	426,308	422,905	1,278,924
General and administrative [Member]
Stockholders' Equity (Details) - Schedule of stock-based compensation expense [Line Items]
Total	$ 899,969	$ 548,388	$ 1,986,161	$ 1,645,167

Collaborative Agreements (Detai

Collaborative Agreements (Details) - USD ($)	1 Months Ended	3 Months Ended	9 Months Ended	12 Months Ended
	Sep. 30, 2020	Sep. 30, 2020	Sep. 30, 2020	Dec. 31, 2019	Sep. 30, 2019
Collaborative Agreements (Details) [Line Items]
Grand award,description	the Company was awarded a grant of up to $2.9 million from the National Institutes of Health (NIH), of which the Company expects to receive approximately $0.7 million in 2020, approximately $1.2 million in 20201 and approximately $1.0 million in 2022. The grant will support a Phase 2 study of XPro1595 in patients with treatment resistant depression. As of September 30, 2020, the Company has not received any proceeds pursuant to this grant.		the Company was awarded a $500,000 grant from the Amyotrophic Lateral Sclerosis (“ALS”) Association to fund a study of the efficacy of XPro1595 to reverse ALS in vitro and to fund a study of the efficacy of XPro1595 to protect against ALS model phenotypes in vivo. During the nine months ended September 30, 2020, the Company received $300,000 of cash proceeds pursuant to this grant which the Company recorded as deferred liabilities.	the Company was awarded a $1,000,000 grant from the Alzheimer’s Association to advance XPro1595, a novel therapy targeting neuroinflammation as a cause of Alzheimer’s disease. The endowment was awarded under the Part the Cloud to RESCUE grant.
Grants received	$ 150,000	$ 150,000	$ 150,000		$ 600,000
Amount of reduction of deferred liabilities		$ 110,878	110,878
Alzheimer’s Association [Member]
Collaborative Agreements (Details) [Line Items]
Cash proceeds			1,000,000
ALS grant [Member]
Collaborative Agreements (Details) [Line Items]
Deferred liability			$ 189,122